Sensei Financial Statements From 2010 to 2025

SNSE Stock  USD 0.45  0.01  2.17%   
Sensei Biotherapeutics financial statements provide useful quarterly and yearly information to potential Sensei Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Sensei Biotherapeutics financial statements helps investors assess Sensei Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sensei Biotherapeutics' valuation are summarized below:
Market Capitalization
11.6 M
Earnings Share
(1.17)
There are over one hundred nineteen available fundamental trend indicators for Sensei Biotherapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of Sensei Biotherapeutics' current performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of February 27, 2025, Market Cap is expected to decline to about 50 M. In addition to that, Enterprise Value is expected to decline to about 39.3 M
Check Sensei Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sensei Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 4.2 M, Depreciation And Amortization of 4.4 M or Interest Expense of 123.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.28. Sensei financial statements analysis is a perfect complement when working with Sensei Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Sensei Biotherapeutics Correlation against competitors.
For information on how to trade Sensei Stock refer to our How to Trade Sensei Stock guide.

Sensei Biotherapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets67.9 M85.5 M33.7 M
Slightly volatile
Short and Long Term Debt Total5.1 M5.6 M5.4 M
Pretty Stable
Other Current Liabilities1.8 M1.7 M586.1 K
Slightly volatile
Total Current Liabilities6.5 M5.1 M5.1 M
Slightly volatile
Other Liabilities127.4 K134.1 K689.8 K
Slightly volatile
Property Plant And Equipment Net4.2 M8.1 M2.3 M
Slightly volatile
Accounts Payable3.1 M1.9 M1.9 M
Slightly volatile
Cash10.2 M15 M5.4 M
Slightly volatile
Non Current Assets Total4.4 M8.2 M2.6 M
Slightly volatile
Non Currrent Assets Other73.5 K77.4 K305.9 K
Slightly volatile
Long Term Debt484.8 K510.3 K2.5 M
Slightly volatile
Cash And Short Term Investments45.6 M75.6 M23.4 M
Slightly volatile
Common Stock Shares Outstanding26.9 M32.1 M13.2 M
Slightly volatile
Liabilities And Stockholders Equity67.9 M85.5 M33.7 M
Slightly volatile
Non Current Liabilities Total3.3 M3.5 M38.3 M
Slightly volatile
Other Current Assets1.4 M1.7 M741.3 K
Slightly volatile
Total Liabilities8.1 M8.5 M43.3 M
Slightly volatile
Property Plant And Equipment Gross10.6 M10.1 M3.1 M
Slightly volatile
Short and Long Term Debt19.4 M18.5 M7.8 M
Slightly volatile
Total Current Assets63.5 M77.3 M31.1 M
Slightly volatile
Non Current Liabilities Other57.3 K60.3 K393.6 K
Slightly volatile
Short Term Debt3.3 M2.2 M2.2 M
Slightly volatile
Property Plant Equipment5.6 M5.3 M1.7 M
Slightly volatile
Capital Lease Obligations4.6 M7.1 M1.9 M
Slightly volatile

Sensei Biotherapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.4 M4.2 M941.1 K
Slightly volatile
Interest Expense123.1 K129.6 K510.9 K
Very volatile
Selling General Administrative12.9 M21.5 M8.8 M
Slightly volatile
Other Operating Expenses30.9 M42.6 M21.5 M
Slightly volatile
Research Development18 M21 M12.7 M
Slightly volatile
Total Operating Expenses30.9 M42.6 M21.5 M
Slightly volatile
Reconciled Depreciation1.7 M1.6 M457.5 K
Slightly volatile
Income Tax Expense85.5 K90 K415 K
Very volatile
Cost Of Revenue736.1 K656.6 K337.2 K
Slightly volatile
Selling And Marketing Expenses80 K90 K98.1 K
Slightly volatile

Sensei Biotherapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.6 M5.1 M2.4 M
Slightly volatile
Begin Period Cash Flow21.5 M20.5 M11 M
Slightly volatile
Depreciation1.6 M1.6 M452.9 K
Slightly volatile
Capital Expenditures196.7 K207 K279.3 K
Slightly volatile
End Period Cash Flow10.2 M15 M5.4 M
Slightly volatile
Change To Netincome3.9 M6.6 M2.9 M
Slightly volatile
Other Non Cash Items906.2 K542.7 K1.3 M
Slightly volatile
Issuance Of Capital Stock85590035.7 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.150.13321.0292
Very volatile
Payables Turnover0.150.30.1189
Slightly volatile
Cash Per Share1.692.121.5067
Slightly volatile
Days Payables Outstanding1.2 K1.2 K6.4 K
Slightly volatile
Income Quality0.630.850.7847
Very volatile
Current Ratio7.8610.735.0858
Slightly volatile
Graham Number8.729.18107
Slightly volatile
Capex Per Share0.0070.00740.0346
Slightly volatile
Interest Debt Per Share0.250.264.2781
Slightly volatile
Debt To Assets0.09120.0962.2913
Pretty Stable
Days Of Payables Outstanding1.2 K1.2 K6.4 K
Slightly volatile
Ebt Per Ebit1.161.061.0425
Pretty Stable
Quick Ratio7.8610.735.0858
Slightly volatile
Net Income Per E B T1.161.00451.1075
Slightly volatile
Cash Ratio1.262.080.9205
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.910.9945
Slightly volatile
Debt Ratio0.09120.0962.2913
Pretty Stable

Sensei Biotherapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap50 M52.6 M101.7 M
Pretty Stable
Enterprise Value39.3 M41.4 M99.1 M
Pretty Stable

Sensei Fundamental Market Drivers

Cash And Short Term Investments65.8 M

Sensei Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Sensei Biotherapeutics Financial Statements

Sensei Biotherapeutics stakeholders use historical fundamental indicators, such as Sensei Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Sensei Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sensei Biotherapeutics' assets and liabilities are reflected in the revenues and expenses on Sensei Biotherapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sensei Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-4 M-3.8 M
Cost Of Revenue656.6 K736.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Sensei Biotherapeutics is a strong investment it is important to analyze Sensei Biotherapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sensei Biotherapeutics' future performance. For an informed investment choice regarding Sensei Stock, refer to the following important reports:
Check out the analysis of Sensei Biotherapeutics Correlation against competitors.
For information on how to trade Sensei Stock refer to our How to Trade Sensei Stock guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sensei Biotherapeutics. If investors know Sensei will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sensei Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Return On Assets
(0.30)
Return On Equity
(0.51)
The market value of Sensei Biotherapeutics is measured differently than its book value, which is the value of Sensei that is recorded on the company's balance sheet. Investors also form their own opinion of Sensei Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sensei Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sensei Biotherapeutics' market value can be influenced by many factors that don't directly affect Sensei Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sensei Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sensei Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sensei Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.